Israel - engelska - Ministry of Health

padagis israel pharmaceuticals ltd, israel - betahistine dihydrochloride - tablets - betahistine dihydrochloride 16 mg - betahistine - betahistine - meniere's syndrom. symptomatic treatment of peripheral vertigo.

Irland - engelska - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - desloratidine - oral solution - 0.5 mg/ml - other antihistamines for systemic use - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: allergic rhinitis, urticaria

Storbritannien - engelska - myHealthbox

rosemont pharmaceuticals ltd - desloratadine - oral solution - 0.5mg/ml - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: - allergic rhinitis - urticaria

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - hyoscine butylbromide 20mg;  ;  ;   - film coated tablet - 20 mg - active: hyoscine butylbromide 20mg       excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch methylcellulose microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for the relief of stomach ache and pain due to cramps or spasm.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferndale pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram

Israel - engelska - Ministry of Health

rafa laboratories ltd - netupitant; palonosetron as hydrochloride - capsules - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

USA - engelska - NLM (National Library of Medicine)

idorsia pharmaceuticals ltd - daridorexant (unii: lmq24g57e9) (daridorexant - unii:lmq24g57e9) - quviviq is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see clinical studies (14.1)] . quviviq is contraindicated: - in patients with narcolepsy. - in patients with a history of hypersensitivity to daridorexant or any components of quviviq. angioedema with pharyngeal involvement has been reported [see adverse reactions (6.2)] . pregnancy exposure registry there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to quviviq during pregnancy. pregnant women exposed to quviviq and healthcare providers are encouraged to call idorsia pharmaceuticals ltd at 1-833-400-9611. risk summary there are no available data on quviviq use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesi

Israel - engelska - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 100 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.

Israel - engelska - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 50 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.